Stocks News Alert: Denbury Resources Inc. (NYSE:DNR), McDermott International Inc. (NYSE:MDR), Tidewater Inc. (NYSE:TDW), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Crocs (NASDAQ:CROX)

Shares of Denbury Resources (NYSE:DNR) have been given an average recommendation of “Hold” by the seventeen analysts that are covering the company, Denbury Resources Inc. (NYSE:DNR) in last trading activity moved down -0.37% to close at $8.13. Company weekly performance is -2.40% while its quarterly performance stands at -43.58%. Denbury Resources Inc. (NYSE:DNR) is -55.81% away from its 52 week high.

McDermott International (NYSE:MDR) last released its earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.11) by $0.03. The company had revenue of $415.00 million for the quarter, compared to the consensus estimate of $686.50 million. During the same quarter in the prior year, the company posted ($0.27) earnings per share. The company’s quarterly revenue was down 39.6% on a year-over-year basis. Analysts expect that McDermott International will post $-0.48 EPS for the current fiscal year. On last trading day McDermott International Inc. (NYSE:MDR) moved down -0.68% to close at $2.91. Its volatility for the week is 4.81% while volatility for the month is 8.05%. MDR’s sales growth for past 5 years was -3.00% and its EPS growth for past 5 years was -59.80%. McDermott International Inc. (NYSE:MDR) monthly performance is -17.33%.

Tidewater Inc. (NYSE:TDW)’s EVP Bruce Douglas Lundstrom purchased 3,413 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were purchased at an average price of $29.19 per share, for a total transaction of $99,625.47. Tidewater Inc. (NYSE:TDW) has 0.60% insider ownership while its institutional ownership stands at 96.50%. In last trading activity company’s stock closed at $32.41.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), a biopharmaceutical company, announces that its partner Spectrum Pharmaceuticals has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Captisol-enabled Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. Spectrum is also seeking approval for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. On Wednesday shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) closed at $53.21. Company’s sales growth for last 5 years was 12.40% and EPS growth for next 5 years is recorded as 48.09%.

Crocs, Inc. (NASDAQ:CROX)’s CFO Jeff Lasher sold 5,082 shares of the company’s stock on the open market in a transaction dated Monday, December 15th. The stock was sold at an average price of $12.17, for a total transaction of $61,847.94. On last trading day Crocs, Inc. (NASDAQ:CROX) advanced 0.16% to close at $12.49. Its volatility for the week is 1.57% while volatility for the month is 2.50%. CROX’s sales growth for past 5 years was 10.60% and its EPS growth for past 5 years was 15.50%. Crocs, Inc. (NASDAQ:CROX) monthly performance is -3.48%.

Leave a Reply

Your email address will not be published. Required fields are marked *

*